Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 19 May
    2015

    FDA grants Orphan Drug Designation to Diurnal for Infacort®

    Cardiff, UK - Diurnal Limited (“Diurnal” or “the Company”) today announced that it has been granted Orphan Drug Designa...

    Read More

  • 24 Apr
    2015

    Diurnal Ltd announces new non-executive director

    Cardiff, UK – Diurnal Limited, a specialty pharmaceutical company dedicated to developing high-quality hormone therapeu...

    Read More

  • 22 Apr
    2015

    Diurnal announces Chief Financial Officer appointment

    Cardiff, UK – Diurnal Limited, a specialty pharmaceutical company committed to the development and commercialization of...

    Read More